Both the 60- and 120-actuation sizes have been discontinued.
Ranolazine, an antianginal drug, has been added as a new contraindication. The labeling states that concomitant use has potential for serious and/or life-threatening reactions.
The Food and Drug Administration (FDA) has approved supplemental Biologics License Applications (sBLA) for Amgen's Prolia (denosumab) and Xgeva (denosumab).
Under drug interactions, new clinical comments regarding concomitant systemic/inhaled/nasal/ophthalmic corticosteroids have been added.